TrialClinical pharmacokinetics2017

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.

Tim Heise et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.